Zontivity

RSS

Withdrawn

This medicine's authorisation has been withdrawn

vorapaxar
MedicineHumanWithdrawn

Lithuanian is available via eTranslation, the European Commission's machine translation service.

Translate to Lithuanian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 23 June 2017 the European Commission withdrew the marketing authorisation for Zontivity (vorapaxar) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp & Dohme Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Zontivity was granted marketing authorisation in the EU on 19 January 2015 for the reduction of atherothrombotic events in adult patients with a history of myocardial infarction. The approved indication was subsequently extended to include adult patients with symptomatic peripheral arterial disease. 

The European Public Assessment Report (EPAR) for Zontivity is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (633.29 KB - PDF)

Rodyti

español (ES) (547.87 KB - PDF)

Rodyti

čeština (CS) (614.5 KB - PDF)

Rodyti

dansk (DA) (545.41 KB - PDF)

Rodyti

Deutsch (DE) (550.79 KB - PDF)

Rodyti

eesti (ET) (544.17 KB - PDF)

Rodyti

ελληνικά (EL) (636.04 KB - PDF)

Rodyti

français (FR) (549.89 KB - PDF)

Rodyti

hrvatski (HR) (573.91 KB - PDF)

Rodyti

italiano (IT) (545.6 KB - PDF)

Rodyti

latviešu (LV) (614.26 KB - PDF)

Rodyti

lietuvių (LT) (574.98 KB - PDF)

Rodyti

magyar (HU) (611.07 KB - PDF)

Rodyti

Malti (MT) (617.97 KB - PDF)

Rodyti

Nederlands (NL) (547.11 KB - PDF)

Rodyti

polski (PL) (612.51 KB - PDF)

Rodyti

português (PT) (548.44 KB - PDF)

Rodyti

română (RO) (575.49 KB - PDF)

Rodyti

slovenčina (SK) (612.69 KB - PDF)

Rodyti

slovenščina (SL) (607.05 KB - PDF)

Rodyti

suomi (FI) (545.31 KB - PDF)

Rodyti

svenska (SV) (546.74 KB - PDF)

Rodyti

Product information

български (BG) (1.9 MB - PDF)

Rodyti

español (ES) (1.26 MB - PDF)

Rodyti

čeština (CS) (1.65 MB - PDF)

Rodyti

dansk (DA) (1.33 MB - PDF)

Rodyti

Deutsch (DE) (1.34 MB - PDF)

Rodyti

eesti (ET) (1.15 MB - PDF)

Rodyti

ελληνικά (EL) (1.99 MB - PDF)

Rodyti

français (FR) (1.22 MB - PDF)

Rodyti

hrvatski (HR) (1.31 MB - PDF)

Rodyti

italiano (IT) (1.32 MB - PDF)

Rodyti

latviešu (LV) (1.68 MB - PDF)

Rodyti

lietuvių (LT) (1.29 MB - PDF)

Rodyti

magyar (HU) (1.72 MB - PDF)

Rodyti

Malti (MT) (1.81 MB - PDF)

Rodyti

Nederlands (NL) (1.29 MB - PDF)

Rodyti

polski (PL) (1.8 MB - PDF)

Rodyti

português (PT) (1.18 MB - PDF)

Rodyti

română (RO) (1.33 MB - PDF)

Rodyti

slovenčina (SK) (1.6 MB - PDF)

Rodyti

slovenščina (SL) (1.64 MB - PDF)

Rodyti

suomi (FI) (1.3 MB - PDF)

Rodyti

svenska (SV) (1.15 MB - PDF)

Rodyti

Íslenska (IS) (1.27 MB - PDF)

Rodyti

norsk (NO) (1.26 MB - PDF)

Rodyti
Latest procedure affecting product information:II/0005
29/07/2016
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (517.85 KB - PDF)

Rodyti

español (ES) (479.2 KB - PDF)

Rodyti

čeština (CS) (495.84 KB - PDF)

Rodyti

dansk (DA) (478.74 KB - PDF)

Rodyti

Deutsch (DE) (476.03 KB - PDF)

Rodyti

eesti (ET) (476.56 KB - PDF)

Rodyti

ελληνικά (EL) (513.72 KB - PDF)

Rodyti

français (FR) (479.35 KB - PDF)

Rodyti

hrvatski (HR) (493.84 KB - PDF)

Rodyti

italiano (IT) (475.94 KB - PDF)

Rodyti

latviešu (LV) (509.36 KB - PDF)

Rodyti

lietuvių (LT) (497.93 KB - PDF)

Rodyti

magyar (HU) (495.04 KB - PDF)

Rodyti

Malti (MT) (503.26 KB - PDF)

Rodyti

Nederlands (NL) (477.88 KB - PDF)

Rodyti

polski (PL) (506.04 KB - PDF)

Rodyti

português (PT) (478.9 KB - PDF)

Rodyti

română (RO) (493.84 KB - PDF)

Rodyti

slovenčina (SK) (497.53 KB - PDF)

Rodyti

slovenščina (SL) (496.4 KB - PDF)

Rodyti

suomi (FI) (480.42 KB - PDF)

Rodyti

svenska (SV) (476.2 KB - PDF)

Rodyti

Íslenska (IS) (476.36 KB - PDF)

Rodyti

norsk (NO) (475.54 KB - PDF)

Rodyti

Product details

Name of medicine
Zontivity
Active substance
vorapaxar sulfate
International non-proprietary name (INN) or common name
vorapaxar
Therapeutic area (MeSH)
Myocardial Infarction
Anatomical therapeutic chemical (ATC) code
B01

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Zontivityis indicated for the reduction of atherothrombotic events in adult patients with

  • a history of myocardial infarction (MI), ,co-administered with acetylsalicylic acid (ASA) and, where appropriate, clopidogrel; or
  • symptomatic peripheral arterial disease (PAD), co-administered with acetylsalicylic acid (ASA) or, where appropriate, clopidogrel.

Authorisation details

EMA product number
EMEA/H/C/002814
Marketing authorisation holder
Merck Sharp Dohme Limited

Hertford Road
EN11 9BU Hoddesdon
United Kingdom

Marketing authorisation issued
19/01/2015
Withdrawal of marketing authorisation
23/06/2017
Revision
2

Assessment history

This page was last updated on

Share this page